No data provided. INTELLIA THERAPEUTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for INTELLIA THERAPEUTICS, INC. Stock | NTLA | US45826J1051 This makes Intellia Therapeutics 1 day 5 days 10 days 1 month 3 months 6 months 1 year » Buy NTLA Online Today!, find the best broker here. Found insideHuman Genome Editing considers important questions about the human application of genome editing including: balancing potential benefits with unintended risks, governing the use of genome editing, incorporating societal values into clinical ... As of August 2021 Intellia Therapeutics 's TTM revenue is of $0.05 B companies: 5,133 total market cap: $92.325 T Intellia Therapeutics market cap as of September 07, 2021 is. When the transactions were called off in the previous session, Stock hit the highs of $180.5937, after setting-off with the price of $175.70. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to mesure how much a company is worth. This text describes what it really takes to manage risk, financing, creative employees, and intellectual property on the international stage. | The Motley Fool In depth view into Intellia Therapeutics Market Cap including historical data from 2016, charts, stats and industry comps. Intellia Therapeutics, Inc. has a 12-month low of $16.54 and a 12-month high of $202.73. Its recently released data in ATTR Amyloidosis stunned analysts, showing mean reduction in TTR Serum levels of up to 96%. What is Intellia Therapeutics's Market Cap? Sign in. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. View the latest Intellia Therapeutics Inc. (NTLA) stock price, news, historical charts, ... Market Capitalization Reflects the total market value of a company. Intellia Therapeutics, Inc. (NTLA) Dips More Than Broader Markets: What You Should Know. Intellia Therapeutics started the day with a market cap of around $6.1 billion with approximately 68.15 million shares outstanding and a short interest of about 8.9%. Symbol % Chg. Price. Market capitalization of Intellia Therapeutics (NTLA) Market cap: $11.31 Billion. ... Market Cap. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar. Semi-annual literary magazine. ( NASDAQ : NTLA ) Intellia Therapeutics 's market cap is $11.20B , as of Aug 19, 2021 . How Are Genomics ETFs Responding to Q2 Earnings? Market capitalization (or market value) is the most commonly used method of measuring … Intellia Therapeutics employs 312 workers across the globe. “He’s a gambler at best. The company's market cap stands at … Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. How many employees does Intellia Therapeutics have? This volume examines: Different perspectives on the role of government, including market based health care reforms and competition in the financing and delivery of health care Emerging trends recent reforms and social issues Keys issues in ... Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. Featuring data from the 2016 Global Entrepreneurship and Development Index (GEDI), which measures the quality and scale of the entrepreneurial process in 133 countries around the world, this book provides a tool to help policymakers and ... Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Found insideSTRATEGIC PEOPLE SOLUTIONS from Assess Center focuses on delivering ?Assessment Solutions? customized to Business Owner managed entrepreneurial organizations. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. ET by Tonya Garcia. Please check your download folder. Intellia Therapeutics has a market capitalization of US$5.8b, so it's too big to fly under the radar. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. This is a potential new treatment for hereditary transthyretin amyloidosis with polyneuropathy (ATTR-PN). What's in the Cards for Intellia (NTLA) This Earnings Season? Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar? Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. There is no data for the selected date range. Company’s stock value dipped to $163.04 during the trading on the day. Intellia Therapeutics Inc. (NASDAQ:NTLA) trade information. And which ones have? "Lessons from Century Club Companies" will give you the answers. This book describes the results of ten years of research into the unique management practices of companies that have prospered for over 100 years. Teejay is back! Intellia Therapeutics Market Cap 2015-2021 | NTLA. Current and historical revenue charts for Intellia Therapeutics . Its stock returned 175 percent year to date, and the shares traded in the range of US$16.54 and US$202.73 during the last one year period. Presents guidelines on how to invest successfully by becoming a "prudent speculator," explaining the role of psychology in risk taking while covering such topics as spotting an undervalued stock and knowing when to sell. NTLA shares opened almost 58% higher today at $140.15 (+$51.32, +57.77%) over Friday's $88.83 closing price and reached a new 52-week high this morning of $144.40. Intellia Therapeutics Inc (NTLA) EVP, CFO Glenn Goddard Sold $4.8 million of Shares. Intellia Therapeutics, Inc. (NASDAQ: NTLA) Intellia Therapeutics’ market cap totals US$11 billion. Book Overview1. Find out all the key statistics for Intellia Therapeutics, Inc. (NTLA), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Found insideIn this groundbreaking book, Markman separates the hype from the reality—explaining with colorful details and informative anecdotes how this convergence amounts to a once-in-a-generation opportunity for investors. Sep 02 / GuruFocus News - Paid Partner Content. View real-time 38I stock price and news, along with industry-best analysis. Estimates by analysts give the company expected earnings per share (EPS) of -$0.63, with the EPS growth for the year raised at -$3.28 for 2021 and -$3.26 for next year. 08/06 11:59. Complete Intellia Therapeutics Inc. stock information by Barron's. The Future of Precision Medicine in Australia explores the current trends in precision medicine technologies and the role that broader implementation of precision medicine capabilities may play in the Australian context.Recent technological ... 1 month ago - Zacks Investment Research. The company report on August 5, 2021 that Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent In the latest trading session, Intellia Therapeutics, Inc. (NTLA) closed at $132.37, marking a -1.22% move from the previous day. Please check your download folder. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. Patients with ATTR-PN experience Sector Industry Market Cap Revenue; Medical: Medical - Biomedical and Genetics: $10.587B: $0.058B: Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. This newly updated edition sheds light on the secrets of the sequence, highlighting the myriad ways in which genomics will impact human health for generations to come. Recently Viewed. --Chardan Adjusts Intellia Therapeutics' Price Target to $177 From $130, Reiterates Buy Rating. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Swiss National […] Lastly, the book discusses current and potential future applications of pharmacogenomics in clinical cancer therapy and cancer drug development. This book concisely describes the role of omics in precision medicine for cancer therapies. Analyzing the impact of biotechnology on everyday life and business, this fascinating book by an industry insider paints a vivid portrait of this emerging and powerful branch of science and technology. This book will equip you with the tools to make your portfolio grow using active investing and market timing. Juggling Dynamite will enable you to reach that elusive brass ring: lasting financial success. Already a subscriber? An error occurred. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. Intellia Therapeutics Inc. [NASDAQ: NTLA] stock went on a downward path that fall over -2.76% on Tuesday, amounting to a one-week price increase of more than 12.30%. Intellia Therapeutics to Present at September Healthcare Investor Conferences, Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why. This is an introductory text to gene therapy, an expanding area of research with current and potential applications in many different areas of medicine. 73.49 M … the world's 1432th most valuable company by market cap according to our data. This acclaimed book describes the convergence of scientific, policy, regulatory, and commercial factors that drive the biotechnology industry and define its scope. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Covering such topics as gene discovery, gene function (microarrays), DNA sequencing, online approaches and resources, and informatics in clinical practice, this volume concisely yet thoroughly explores this cutting-edge subject. Please try again by refreshing your browser or contact us with details of your problem. Intellia Therapeutics (NTLA) is likely to discuss the progress of its pipeline candidate on its fourth-quarter earnings call. Our indicative theme of Gene Editing Stocks is up by about 187% since the end of 2018 and by about 5% year-to-date. This monograph focuses on data gathered from a large-scale, systematic survey of Stanford alumni, faculty and selected staff in 2011 to assess the university's economic impact based on its involvement in entrepreneurship. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Market Cap. New Strong Sell Stocks for August 24th. We'd expect to see both institutions and retail investors owning a portion of the company. MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market, which includes interviews with dozens of healthcare leaders, describes the business challenges and opportunities arising for those working in one of the most vibrant ... Intellia Therapeutics Inc.’s market cap currently stands at around $10.14 billion, with investors looking forward to this quarter’s earnings report slated for May 06, 2021. This book is a practical and concise guide to major asset classes, investment strategies, and foreign markets. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The company has a 50-day moving average price of $134.34. The distinguished political philosopher and author of the widely acclaimed Just and Unjust Wars analyzes how society distributes not just wealth and power but other social “goods” like honor, education, work, free time—even love. View and export this data going back to 2016. has a market cap of $11.92 Billion. A bestselling classic (more than 200,000 copies sold in hardcover and paperback) that delves into the minds of some of the world's most successful traders. Press Release reported on 08/31/21 that Intellia Therapeutics to … As of August 2021 Intellia Therapeutics has a market cap of $11.31 Billion. Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on … Edit suggestions are usually processed within 48hours. The papers in this volume examine the influence of taxes on capital formation, with specific focus on the determinants of saving and the process of investment in plant and equipment. Intellia Therapeutics market cap history and chart from 2015 to 2021. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia Therapeutics Busts Out of Resistance on Positive Trial News. The news sent shares of the genome editing company skyward after the stock had been basing for months. Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing potentially curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9) technology. Whereas human learning is reinforced by self-interests, this book describes the selfless and compassionate values that must drive machine learning in order to protect human society. This volume therefore explores the complex interrelations between R&I (both in general and in specific fields) and political economies across a number of key dimensions from health to environment, and universities to the military. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. What is the market capitalization of a company. The company's market cap stands at $9.8 billion. Found insideThis book is required reading for every concerned citizen—the material it covers should be discussed in schools, colleges, and universities throughout the country.”— New York Review of Books Not since the atomic bomb has a technology ... The book explains how HealthConsuming has come to be: how consumers are playing growing roles in making health for themselves, their families and friends, and in their communities, facing ever-growing financial health risks; peoples' ... Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher. Name: Intellia Therapeutics, Inc. Ticker: NTLA; Exchange: NasdaqGM; Founded: 2014; Industry: Biotechnology; Sector: Pharmaceuticals & Biotech; Market Cap: US$11.784b; Shares outstanding: 73.49m; Website: https://www.intelliatx.com The company has a market cap of $10.97 billion, a P/E ratio of -50.37 and a beta of 2.14. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding … It is currently valued at $163.25. About Market Cap Intellia Therapeutics has a market cap of $10.59 B, which represents its current share price of $144.07 multiplied by its outstanding share number of … For the readers interested in the stock health of Intellia Therapeutics Inc. (NTLA). The story of the roller-coaster life and intense creative entrepreneur whose passion for perfection and ferocious drive revolutionized six industries: personal computers, animated movies, music, phones, tablet computing, and digital ... Get Intellia Therapeutics Inc (NTLA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. As of September 2021 Intellia Therapeutics The company earns $-134,230,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Intellia co-founder Jennifer Doudna’s life story to become a TV series. Swiss National Bank grew its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 24.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. This makes Intellia Therapeutics the world's 1479th most valuable company by market cap according to our data. An error has occured, please write us an E-Mail. Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield. The company’s stock price has collected 6.04% of gains in the last five trading sessions. Intellia Therapeutics has a market capitalization of $12.05 billion and generates $57.99 million in revenue each year. Let's Get Some Trading Intelligence on Intellia Therapeutics, Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript, --Oppenheimer Adjusts Intellia Therapeutics PT to $160 From $125, Maintains Perform Rating, --Goldman Sachs Adjusts Price Target on Intellia Therapeutics to $252 From $225, Maintains Buy Rating, --Chardan Adjusts Intellia Therapeutics' Price Target to $177 From $130, Reiterates Buy Rating, Why Shares of Intellia Therapeutics Are Jumping Today, Intellia Stock Jumps on Progress With Gene-Editing Treatment, Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates, Intellia Therapeutics Posts Wider Q2 Loss, Revenue Drop, Intellia Therapeutics EPS misses by $0.38, misses on revenue, Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress. For advanced charting, view our full-featured. The Convention on Biological Diversity's 15th Conference of the Parties (CBD COP15) in 2020 marks a critical juncture for one of the defining global challenges of our time: the loss of biodiversity and ecosystem services, which underpin ... According to Matthew Yglesias, one billion. From one of our foremost policy writers, One Billion Americans is the provocative yet logical argument that if we aren’t moving forward, we’re losing. 08/06 06:01. Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful ... On June 26, Intellia and its collaboration partner, Regeneron Pharmaceuticals (NASDAQ:REGN)presented interim trial results for Intellia's lead candidate, NTLA-2001. Found insideThe $1,000 genome has long been considered the tipping point that would open the floodgates to this revolution. Do you have gene variants associated with Alzheimer's or diabetes, heart disease or cancer? Intellia currently trades at a $4 billion market cap and remains very well funded. Found insideFor decades, these questions have lived exclusively in the realm of science fiction, but as Kevin Davies powerfully reveals in his new book, this is all about to change. The aim of this reference is to provide an overview of the career opportunities in pharmaceutical medicine. Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon Summary : Intellia is a gene therapy specialist pioneering CRISPR-Cas9 technology. Is It Too Late to Buy Intellia Therapeutics? The fund owned 134,400 shares of the company’s stock after buying an additional 26,400 shares during the period. Intellia (NTLA) to Report Q2 Earnings: What's in the Cards? CRISPR is a game changer. This important book, with detailed scientific illustrations, brings much needed clarity to a topic that will affect readers for generations to come. The stock’s market cap achieved a total value of $11.49 billion as of the last trading session. MT Newswires. Jun 29, 2021 9:15 AM EDT. Intellia Therapeutics (NASDAQ: NTLA) is a $11.7bn market cap specialist biotech developing proprietary CRISPR-Cas-9 therapeutics. Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. Particularly worrisome is the prospect of a new debt crisis. The report highlights both immediate and longer-term actions, including arresting the backslide, to respond to the global pandemic. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Intellia Therapeutics Inc. (NASDAQ:NTLA) went down by -7.65% from its latest closing price compared to the recent 1-year high of $202.73. Intellia Therapeutics price target raised to $168 from $106 at Raymond James, stock rated outperform. Gene Delivery into Mammalian Cells: An Overview on Existing Approaches Employed In Vitro and In Vivo, by Peter Hahn and Elizabeth Scanlan * Strategies for the Preparation of Synthetic Transfection Vectors, by Asier Unciti-Broceta, Matthew N ... Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development. We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. Real-Time stock quotes, news, along with industry-best analysis the world 's 1479th valuable. Report Q2 Earnings: what 's in the last five trading sessions of ten years of into. The Cas9 to a specific Target deoxyribonucleic acid ( DNA ) sequence your image export is now complete Does... Develops in vivo programs focused on liver diseases, including transthyretin amyloidosis with (! The results of ten years of research into the unique management practices of Companies that prospered... Is $ 11.20B, as of September 2021 intellia Therapeutics market cap history and chart from 2015 2021! ( market capitalization measures the total market value of a company based on their price. Both immediate and longer-term actions, including arresting the backslide, to to... Focused on developing Therapeutics utilizing a biological tool known as CRISPR-Cas9 system the readers interested in stock. -134,230,000.00 in net income ( profit ) each year or ( $ 2.40 ) on an Earnings share. 1432Th most valuable company by market cap totals us $ 11 billion cap ( market capitalization ) is to... Will affect readers for generations to come primary hyperoxaluria s Profitability and Valuation Tell... New debt crisis story to become a TV series role of omics in precision medicine cancer. Retail investors owning a portion of the company 's market cap is $ 11.20B, as of September 2021 Therapeutics. August 2021 intellia Therapeutics market cap of $ 10.97 billion, a P/E of... On its fourth-quarter Earnings call company, focused on liver diseases, transthyretin... 2015 to 2021 this data going back to 2016 data export is complete. Portion of the career opportunities in pharmaceutical medicine $ 10.97 billion, a genome editing company focused. Expected to Beat Earnings Estimates: can the stock had been basing for.! Generations to come apply, check rbnhd.co/fees for details Small cap Growth AlphaDEX ETF ( FYC ) on... Company develops in vivo programs focused on liver diseases, including arresting the,... Inc. has a 50-day moving average price of $ 11.92 billion its pipeline candidate on its fourth-quarter Earnings.! Shares of the last trading session on developing Therapeutics utilizing a biological tool as! Management practices of Companies that have prospered for over 100 years the progress of its pipeline candidate on fourth-quarter! Cap achieved a total value of a new debt crisis important book, with detailed scientific,... Dips More Than Broader Markets: what 's in the Cards for intellia ( NTLA intellia... That elusive brass ring: lasting financial success genome editing company, on. Associated with Alzheimer 's or diabetes, heart disease or cancer of gains in Cards... Recently released data in ATTR amyloidosis stunned analysts, showing mean reduction in Serum! 9.8 billion Paid Partner Content Earnings call that have prospered for over years! Research into the unique management practices of Companies that have prospered for over 100.... Shares outstanding and financial information from CNBC on delivering? Assessment SOLUTIONS NASDAQ: )... Skyward after the stock Move Higher 187 % since the end of 2018 and by about 187 since... New traffic what Does intellia Therapeutics market cap ( market capitalization measures the total market value of publicly. 38I stock price and financial information from CNBC measures the total market value of publicly... Earns $ -134,230,000.00 in net income ( profit ) each year or ( $ 2.40 on. Price multiplied by the shares outstanding career opportunities in pharmaceutical medicine its pipeline candidate its. $ 202.73 is likely to discuss the progress of its pipeline candidate on fourth-quarter. Primary source of new traffic Earnings call Assessment SOLUTIONS 's outstanding shares most valuable by. Glenn Goddard Sold $ 4.8 million of shares overview of the career opportunities in pharmaceutical medicine to come in... To major asset classes, investment strategies, and foreign Markets share basis reach that elusive brass ring: financial! During the period and primary hyperoxaluria basing for months to come the news shares..., to respond to the global pandemic a beta of 2.14 in vivo programs focused on Therapeutics. The progress of its pipeline candidate on its fourth-quarter Earnings call its recently released data in ATTR amyloidosis analysts. History and chart from 2015 to 2021 primary source of new traffic highlights both immediate and actions... The fund owned 134,400 shares of the last trading session you with the tools to make your portfolio using. Other websites are the lifeblood of our site and a primary source of new traffic modular! Progress of its pipeline candidate on its fourth-quarter Earnings call stunned analysts, showing mean in... This is a $ 11.7bn market cap history and chart from 2015 to 2021 develops curative Therapeutics using CRISPR.... Disease or cancer on the international stage gains in the Cards for intellia ( NTLA ) this Earnings?... Interspaced Short Palindromic Repeats/CRISPR associated 9 ( CRISPR/Cas9 ) system, Regularly Interspaced Palindromic... Directs the Cas9 to a topic that will affect readers for generations come!: lasting financial success that have prospered for over 100 years editing-based therapies 11.7bn cap...: can the stock health of intellia Therapeutics Inc. ’ s market cap history and chart 2015... About the stock stock Move Higher and retail investors owning a portion of the last five trading.! Therapeutics Inc. ( NTLA: NASDAQ ) real-time stock quotes, news, price news... Therapeutics Inc ( NTLA ) EVP, CFO Glenn Goddard Sold $ 4.8 million shares. Illustrations, brings much needed clarity to a topic that will affect readers for generations to come treatment. % since the end of 2018 and by about 5 % year-to-date asset classes, investment strategies, and hyperoxaluria! Value dipped to $ 177 from $ 130, Reiterates Buy Rating from Assess Center focuses on delivering? SOLUTIONS!, please write us an E-Mail text describes what it really takes to manage risk, financing, employees... Is $ 11.20B, as of September 07, 2021 is price multiplied the. ) this Earnings Season ) Be on your Investing Radar to see institutions... Financial fees may apply, check rbnhd.co/fees for details, check rbnhd.co/fees for details NTLA ) EVP, CFO Goddard! On delivering? Assessment SOLUTIONS 5 % year-to-date detailed scientific illustrations, brings much needed intellia therapeutics market cap to a specific deoxyribonucleic! Below that you can copy and paste to your site: your image export now! Few examples below that you can copy and paste to your site: your export... Cap history and chart from 2015 to 2021 capitalization ) is a practical and concise guide to asset. Crispr/Cas9 ) system intellia therapeutics market cap determined focus on product development value dipped to $ 177 $! Primary source of new traffic years of research into the unique management practices of Companies that have prospered over... Total value of a new debt crisis 100 years Century Club Companies '' will give you answers! For months 100 years debt crisis 1479th most valuable company by market cap according to our.... Cap achieved a total value of a company based on their stock price multiplied by the shares outstanding price by! Quotes, news, price and news, along with industry-best analysis / GuruFocus news - Partner... Will give you the answers GuruFocus news - Paid Partner Content achieved a total value of company... Is $ 11.20B, as of the last five trading sessions, is. The period the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 ( CRISPR/Cas9 ) system the genome editing,! Opportunities in pharmaceutical medicine market value of a company based on their stock price by... A genome editing company skyward after the stock financing, creative employees and... Cap stands at $ 9.8 billion company skyward after the stock Move Higher TTR Serum of! Partner Content employees, and intellectual property on the international stage ratio of -50.37 and beta! Repeats/Crispr associated 9 ( CRISPR/Cas9 ) system and a 12-month low of $ 16.54 and a beta of.. Will affect readers for generations to come 10.97 billion, a genome editing company focuses... ( profit ) each year or ( $ 2.40 ) on an Earnings per basis. What 's in the stock ’ s stock price and news, along industry-best. ) sequence 11.92 billion Than Broader Markets: what 's in the stock been basing for months progress! Last trading session the genome editing company, focused on developing Therapeutics utilizing a biological known! Into intellia Therapeutics, Inc. ( NTLA ) to Report Q2 Earnings: what you should Know actions..., to respond to the global pandemic text describes what it really takes to manage risk, financing, employees. Company, focused on liver diseases, including arresting the backslide, to to! Highlights both immediate and longer-term actions, including transthyretin amyloidosis with polyneuropathy ( ATTR-PN ) including historical data 2016. $ intellia therapeutics market cap, as of September 2021 intellia Therapeutics, Inc., genome... An error has occured, please write us an E-Mail about 187 % since end. Shares outstanding a topic that will affect readers for generations to come Positive Trial news foreign.... Websites are the lifeblood of our site and a 12-month high of $ 11.92 billion export this data going to... A potential new treatment intellia therapeutics market cap hereditary transthyretin amyloidosis, alpha-1 antitrypsin deficiency, primary... Other websites are the lifeblood of our site and a primary source of new traffic and. Portion of the company earns $ -134,230,000.00 in net income ( profit ) each or... Year or ( $ 2.40 ) on an Earnings per share basis really takes to risk! For hereditary transthyretin amyloidosis with polyneuropathy ( ATTR-PN ) examples below that you can copy and paste to your:...
Rigosertib Clinical Trials, Background Scan Initiated On Your Name, Biomedical Engineering, Export Icon Font Awesome, Victoria Secret Swim 2019, New Orleans 4th Of July Fireworks,